Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study

Hepatic arterial infusion chemotherapy (HAIC) using a combination of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) has shown promise for hepatocellular carcinoma (HCC) patients classified under Barcelona Clinic Liver Cancer (BCLC) stage C. In China, the combined therapy of camrelizumab and apat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tian-Qi, Geng, Zhi-Jun, Zuo, Meng-Xuan, Li, Ji-Bin, Huang, Jin-Hua, Huang, Zi-Lin, Wu, Pei-Hong, Gu, Yang-Kui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603153/
https://www.ncbi.nlm.nih.gov/pubmed/37884523
http://dx.doi.org/10.1038/s41392-023-01663-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603153/
https://www.ncbi.nlm.nih.gov/pubmed/37884523
http://dx.doi.org/10.1038/s41392-023-01663-6

Ejemplares similares